Applications of (2S)-4-(1,3-Dioxoisoindolin-2-Yl)-2-Hydroxybutanoic Acid in Industrial Manufacturing

We supply (2S)-4-(1,3-Dioxoisoindolin-2-Yl)-2-Hydroxybutanoic Acid direct from our manufacturing facility to global B2B customers. This advanced chiral intermediate underpins key production processes within pharmaceuticals, peptide synthesis, and specialty chemicals. Each application below details practical downstream usage from established industrial practice, helping technical teams in formulation, quality compliance, and process optimization.

1. Peptide Drug Active Pharmaceutical Ingredient (API) Synthesis

This raw material serves as a protected chiral building block in the synthesis of complex peptide APIs, enabling precise stereochemistry essential for pharmacological activity. In modern solid-phase and solution-phase peptide assembly lines, this intermediate commonly provides phthalimide group protection and ensures downstream functional group selectivity. Industrial peptide manufacturers use this acid during early-stage coupling reactions, integrating it into sequences that undergo multi-step deprotection and elongation. Efficient handling reduces racemization risk and controls byproduct formation at scale.

Industry compliance standards

• ICH Q7 GMP for APIs
• USP/NF for peptide substances
• European Pharmacopoeia 10.0 monographs (peptide APIs)
• FDA 21 CFR Part 211 Controls for Finished Pharmaceuticals

Typical usage ratio

• 0.9–1.05 molar equivalents per protected amino acid residue; adjusted per target peptide length and loading efficiencies

Downstream process integration

• Introduced during the protected amino acid activation step, before solid-phase or solution-phase peptide chain elongation

Final product types

• Pharmaceutical injectable peptides (e.g., GLP-1 analogs)
• Oral small peptide drugs
• Synthetic oligopeptides for pharmaceutical research

2. Custom Chiral Intermediate Production for Small Molecule Pharmaceuticals

This compound acts as a key chiral synthon in the production of enantio-enriched pharmaceutical intermediates, particularly for β-hydroxy carboxylic acid derivatives used in next-generation small molecule drugs. Chemical manufacturers integrate this acid into asymmetric synthesis campaigns, benefiting from its stable protecting group under a variety of coupling, reduction, and resolution conditions. Strict handling protocols govern input material qualification and chain-of-custody to meet drug master file (DMF) standards.

Industry compliance standards

• EU GMP Part II for starting materials
• FDA ICH Q11 Development and Manufacture of Drug Substances
• ISO 9001:2015 Quality Management
• Japanese Pharmacopoeia transparency for chiral intermediates

Typical usage ratio

• Stoichiometric addition: 1 molar equivalent per synthetic route; increased up to 1.2 equivalents when optimizing for high-yield enantioselective transformations

Downstream process integration

• Entered prior to key carbon–carbon bond-forming or reduction step; integrated with chiral pool strategy in multi-step synthetic routes

Final product types

• Finished pharmaceutical bulk intermediates
• API chiral fragments (e.g., for anti-diabetic, anti-viral drugs)
• Reference standards for regulatory submission

3. Specialty Chemical Synthesis: Fine Organic Building Blocks

Producers of advanced fine chemicals use this intermediate in manufacturing libraries of modified butanoic acids and isoindoline derivatives, targeting applications in crop protection R&D and functional material research. Controlled incorporation of the phthalimide-protected moiety enables downstream functionalization—such as substitution, cyclization, or selective deprotection—to access high-purity building blocks demanded by downstream specialty chemical sectors. Analytical traceability and batch reproducibility remain critical during scale-up campaigns for contract synthesis customers.

Industry compliance standards

• ISO 9001:2015 for specialty chemical production
• REACH (EC) No 1907/2006 registration for European market supply
• GHS labeling and hazard communication (CLP Regulation EC 1272/2008)
• Internal QA/QC documented procedures

Typical usage ratio

• 0.8–1.2 molar equivalents relative to main substrate; ratio refined based on downstream derivatization efficiency and impurity profile control

Downstream process integration

• Charged during core scaffolding or initial protection/deprotection sequences; supporting functional diversification in multistep organic synthesis

Final product types

• Custom butanoic acid derivatives for crop science
• Cyclic imide-modified building blocks for material science
• Analytical reference chemicals for research labs

4. Advanced Research Reagent for Academic and Biotech R&D

Academic institutions and biotechnology R&D companies incorporate this chiral acid into synthetic pathways for target validation and structure–activity relationship (SAR) programs. Its defined stereochemistry allows chemists to build structurally complex compounds for bioactive screening, enzyme inhibition studies, or structural motif design. Researchers emphasize precise stoichiometry and analytical rigor to facilitate reproducibility, and procurement must ensure material traceability and documentation to align with funding and publishing mandates.

Industry compliance standards

• GLP (Good Laboratory Practice) for R&D experiments
• ISO/IEC 17025:2017 for laboratory accreditation
• Institutional Material Safety protocols
• Local Chemical Safety and Reporting compliance

Typical usage ratio

• 0.95–1.1 equivalents per coupling; range optimized according to substrate scope, scale, and experimental yield targets

Downstream process integration

• Employed at the initial or intermediate step of multi-step synthesis routes; utilized for protection of hydroxy or amino groups before further modifications

Final product types

• Lead-like research compounds for biological assays
• Reference samples for analytical calibration
• Research materials for grant-funded synthetic projects